About Christina Vorvis
Christina Vorvis is a director at Cloverleaf Bio.
Experience
This experience comes from Christina Vorvis's profile and from SEC filings. For roles taken from filings, the years are when the filings name Christina Vorvis in the role, so the role may have started earlier or lasted longer.
Cloverleaf Bio, Inc. Current
Board Member, Voting
2026 – Present · New Haven, CT
Develops RNA-based cancer treatments for people with cancer.
XT
Xenimmune Therapeutics Current
Board Member, Voting
2024 – Present
AI
Accent Therapeutics, Inc. Current
Board Member, Observer
2023 – Present
AB
AbbVie Current
Director, AbbVie Ventures
2023 – Present
BA
Back Bay Life Science Advisors
Senior Associate, Investment Banking
2021 – 2023
FH
Fitango Health
Chief Operating Officer
2018 – 2021
OR
OrbiMed
Senior Associate, Royalty & Structured Finance
2017 – 2019
AM
Amgen
Associate, In-Licensing, Business Development
2016 – 2017
DI
Dana-Farber Cancer Institute
Research Scientist - Department of Cancer, Immunology, and AIDS
2011 – 2012
VU
Virginia Commonwealth University
Research Scientist - Department of Physiology and Structural Biology
2009 – 2011
Key Colleagues at Startups
The people Christina Vorvis works with at each company, as listed on that company's latest Form D.
Cloverleaf Bio, Inc. · Form D, Sep 9, 2026
DK
Dima Kuzmin
Director
CL
Cole Lewis
Executive officer
MS
Matthias Samwer
Director
AD
Austin Draycott
President and director